Genetic changes in ovarian cancer

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The development of cancer is a multistep process involving accumulation of genetic changes which progressively transform normal cells to neoplastic cells. During the last few years, our understanding and knowledge of the genetic changes involved in ovarian carcinogenesis have increased dramatically. In this review I will focus on karyotypic abnormalities in ovarian cancer and will also refer to molecular studies involving alterations in oncogenes and tumour suppressor genes in ovarian tumori-genesis. Cytogenetic analyses have identified two distinct subgroups. Simple karyotypic changes, trisomy 12 being the most common aberration in this group, are recurrently found in well differentiated ovarian carcinomas. Complex karyotypic abnormalities, including predominantly chromosome losses, deletions and unbalanced translocations, are found in moderately and poorly differentiated carcinomas. The bands and regions most commonly involved in structural rearrangements have been, in decreasing order of frequency, 19p13, 1p36, 1q21, 1q23-25, 3p11-13, 6q21, 19q13, 11p13-15,11q13,11q23,12q24,12p11-13, and 7p13-22. The finding of Identical karyotypic and other genetic changes in tumour samples taken from different sites, such as tumours from both ovaries and omental metastases, indicate that ovarian cancer is of unicentric origin with subsequent metastatic spread giving rise to multiple implants. Molecular genetic changes important In ovarian cancer involve both classes of tumour-associated genes: oncogenes and tumour suppressor genes. In contrast to other tumour types, RAS activation is generally not observed in ovarian cancer. Alterations of MYC1, ERBB2, AKT2, and TP53 has been described in some ovarian carcinomas. The temporal relationship of these mutations, i.e. early or late events in ovarian carcinogenesis, remains to be determined.

Original languageEnglish (US)
Pages (from-to)73-78
Number of pages6
JournalAnnals of Medicine
Volume27
Issue number1
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Neoplasms
Tumor Suppressor Genes
Carcinoma
Oncogenes
Carcinogenesis
Chromosome Deletion
Cytogenetic Analysis
Trisomy
Molecular Biology
Ovary
Neoplasm Metastasis
Mutation
Genes

Keywords

  • Genetic changes
  • Karyotypic abnormalities
  • Ovarian cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic changes in ovarian cancer. / Pejovic, Tanja.

In: Annals of Medicine, Vol. 27, No. 1, 1995, p. 73-78.

Research output: Contribution to journalArticle

Pejovic, Tanja. / Genetic changes in ovarian cancer. In: Annals of Medicine. 1995 ; Vol. 27, No. 1. pp. 73-78.
@article{457294780ec74f6bae4f4594e8e2a7fa,
title = "Genetic changes in ovarian cancer",
abstract = "The development of cancer is a multistep process involving accumulation of genetic changes which progressively transform normal cells to neoplastic cells. During the last few years, our understanding and knowledge of the genetic changes involved in ovarian carcinogenesis have increased dramatically. In this review I will focus on karyotypic abnormalities in ovarian cancer and will also refer to molecular studies involving alterations in oncogenes and tumour suppressor genes in ovarian tumori-genesis. Cytogenetic analyses have identified two distinct subgroups. Simple karyotypic changes, trisomy 12 being the most common aberration in this group, are recurrently found in well differentiated ovarian carcinomas. Complex karyotypic abnormalities, including predominantly chromosome losses, deletions and unbalanced translocations, are found in moderately and poorly differentiated carcinomas. The bands and regions most commonly involved in structural rearrangements have been, in decreasing order of frequency, 19p13, 1p36, 1q21, 1q23-25, 3p11-13, 6q21, 19q13, 11p13-15,11q13,11q23,12q24,12p11-13, and 7p13-22. The finding of Identical karyotypic and other genetic changes in tumour samples taken from different sites, such as tumours from both ovaries and omental metastases, indicate that ovarian cancer is of unicentric origin with subsequent metastatic spread giving rise to multiple implants. Molecular genetic changes important In ovarian cancer involve both classes of tumour-associated genes: oncogenes and tumour suppressor genes. In contrast to other tumour types, RAS activation is generally not observed in ovarian cancer. Alterations of MYC1, ERBB2, AKT2, and TP53 has been described in some ovarian carcinomas. The temporal relationship of these mutations, i.e. early or late events in ovarian carcinogenesis, remains to be determined.",
keywords = "Genetic changes, Karyotypic abnormalities, Ovarian cancer",
author = "Tanja Pejovic",
year = "1995",
doi = "10.3109/07853899509031940",
language = "English (US)",
volume = "27",
pages = "73--78",
journal = "Annals of Medicine",
issn = "0785-3890",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Genetic changes in ovarian cancer

AU - Pejovic, Tanja

PY - 1995

Y1 - 1995

N2 - The development of cancer is a multistep process involving accumulation of genetic changes which progressively transform normal cells to neoplastic cells. During the last few years, our understanding and knowledge of the genetic changes involved in ovarian carcinogenesis have increased dramatically. In this review I will focus on karyotypic abnormalities in ovarian cancer and will also refer to molecular studies involving alterations in oncogenes and tumour suppressor genes in ovarian tumori-genesis. Cytogenetic analyses have identified two distinct subgroups. Simple karyotypic changes, trisomy 12 being the most common aberration in this group, are recurrently found in well differentiated ovarian carcinomas. Complex karyotypic abnormalities, including predominantly chromosome losses, deletions and unbalanced translocations, are found in moderately and poorly differentiated carcinomas. The bands and regions most commonly involved in structural rearrangements have been, in decreasing order of frequency, 19p13, 1p36, 1q21, 1q23-25, 3p11-13, 6q21, 19q13, 11p13-15,11q13,11q23,12q24,12p11-13, and 7p13-22. The finding of Identical karyotypic and other genetic changes in tumour samples taken from different sites, such as tumours from both ovaries and omental metastases, indicate that ovarian cancer is of unicentric origin with subsequent metastatic spread giving rise to multiple implants. Molecular genetic changes important In ovarian cancer involve both classes of tumour-associated genes: oncogenes and tumour suppressor genes. In contrast to other tumour types, RAS activation is generally not observed in ovarian cancer. Alterations of MYC1, ERBB2, AKT2, and TP53 has been described in some ovarian carcinomas. The temporal relationship of these mutations, i.e. early or late events in ovarian carcinogenesis, remains to be determined.

AB - The development of cancer is a multistep process involving accumulation of genetic changes which progressively transform normal cells to neoplastic cells. During the last few years, our understanding and knowledge of the genetic changes involved in ovarian carcinogenesis have increased dramatically. In this review I will focus on karyotypic abnormalities in ovarian cancer and will also refer to molecular studies involving alterations in oncogenes and tumour suppressor genes in ovarian tumori-genesis. Cytogenetic analyses have identified two distinct subgroups. Simple karyotypic changes, trisomy 12 being the most common aberration in this group, are recurrently found in well differentiated ovarian carcinomas. Complex karyotypic abnormalities, including predominantly chromosome losses, deletions and unbalanced translocations, are found in moderately and poorly differentiated carcinomas. The bands and regions most commonly involved in structural rearrangements have been, in decreasing order of frequency, 19p13, 1p36, 1q21, 1q23-25, 3p11-13, 6q21, 19q13, 11p13-15,11q13,11q23,12q24,12p11-13, and 7p13-22. The finding of Identical karyotypic and other genetic changes in tumour samples taken from different sites, such as tumours from both ovaries and omental metastases, indicate that ovarian cancer is of unicentric origin with subsequent metastatic spread giving rise to multiple implants. Molecular genetic changes important In ovarian cancer involve both classes of tumour-associated genes: oncogenes and tumour suppressor genes. In contrast to other tumour types, RAS activation is generally not observed in ovarian cancer. Alterations of MYC1, ERBB2, AKT2, and TP53 has been described in some ovarian carcinomas. The temporal relationship of these mutations, i.e. early or late events in ovarian carcinogenesis, remains to be determined.

KW - Genetic changes

KW - Karyotypic abnormalities

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0028960676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028960676&partnerID=8YFLogxK

U2 - 10.3109/07853899509031940

DO - 10.3109/07853899509031940

M3 - Article

C2 - 7742004

AN - SCOPUS:0028960676

VL - 27

SP - 73

EP - 78

JO - Annals of Medicine

JF - Annals of Medicine

SN - 0785-3890

IS - 1

ER -